益气化瘀解毒方对HP相关性慢性萎缩性胃炎临床疗效及胃蛋白酶原的影响
|
摘要
[目的]观察益气化瘀解毒方对慢性萎缩性胃炎的临床疗效及对血清胃蛋白酶原的影响;[方法]将符合诊断标准的患者,按照随机数字表法分为对照组(61例)和治疗组(59例),其中对照组给予胃复春片口服,治疗组给予益气化瘀解毒方治疗,2组疗程均为12周,分别于治疗前后观察2组患者临床疗效,胃黏膜形态学及血清胃蛋白酶原的变化;[结果]治疗组总有效率为90.16%,明显优于对照组的64.41%;2组治疗后胃黏膜萎缩病理学分级均有不同程度改善,但治疗组效果更为显著;治疗组HP根除率为83.61%高于对照组的61.02%;2组治疗后血清PGⅠ、PGR均上升,治疗组效果更为明显。[结论]益气化瘀解毒方治疗HP相关CAG可以显著改善患者临床症状,根除HP感染、调节胃蛋白酶原水平,临床疗效显著。
[Objective]To observe the clinical effect of Yiqi Huayu Jiedu Decoction on chronic atrophic gastritis and on serum pepsinogen.[Methods]Patients according to the diagnostic criteria were randomly divided into control group(61cases)and treatment group(59cases),the control group was treated with Weifuchun tablet,treatment group were treated with Yiqi Huayu Jiedu Decoction treatment,two groups were treated for 12 weeks,to observe the clinical curative effect of two groups before and after treatment,changes of gastric mucosal morphology and serum pepsinogen raw.[Results]The total efficiency in treatment group was 90.16%,significantly better than the control group 64.41%;gastric mucosa atrophy pathological grading were improved in different degrees after treatment,but the treatment group was more significant;the eradication rate of HP in the treatment group was 61.02% higher than that of the control group;the two groups after treatment,the serum PG I,PGR were higher than before treatment,the treatment group was more obvious.[Conclusion]Yiqi Huayu Jiedu Decoction can significantly improve the clinical symptoms,eradication of HP infection,adjusting pepsinogen levels,and the clinical curative effect is distinct.
[Objective]To observe the clinical effect of Yiqi Huayu Jiedu Decoction on chronic atrophic gastritis and on serum pepsinogen.[Methods]Patients according to the diagnostic criteria were randomly divided into control group(61cases)and treatment group(59cases),the control group was treated with Weifuchun tablet,treatment group were treated with Yiqi Huayu Jiedu Decoction treatment,two groups were treated for 12 weeks,to observe the clinical curative effect of two groups before and after treatment,changes of gastric mucosal morphology and serum pepsinogen raw.[Results]The total efficiency in treatment group was 90.16%,significantly better than the control group 64.41%;gastric mucosa atrophy pathological grading were improved in different degrees after treatment,but the treatment group was more significant;the eradication rate of HP in the treatment group was 61.02% higher than that of the control group;the two groups after treatment,the serum PG I,PGR were higher than before treatment,the treatment group was more obvious.[Conclusion]Yiqi Huayu Jiedu Decoction can significantly improve the clinical symptoms,eradication of HP infection,adjusting pepsinogen levels,and the clinical curative effect is distinct.
引文
[1]中华医学会消化病分会.中国慢性胃炎共识意见[J].胃肠病学,2006,11(11):674-684.
[2]中华医学会消化病学分会.中国慢性胃炎共识意见(2012年,上海)[J].现代消化及介入治疗,2013,18(2):119-128.
[3]王晓倩,盛天骄,林一帆,等.健脾清热化瘀法治疗慢性萎缩性胃炎疗效的Meta分析[J].中国中西医结合消化杂志,2015,23(10):678-681.
[4]王胜球,陈柏荣,梁子彬,等.益生菌联合序贯疗法治疗幽门螺杆菌相关性慢性萎缩性胃炎的疗效与安全性分析[J].中国中西医结合消化杂志,2015,23(2):88-90.
[5]中华医学会消化病学分会.中国慢性胃炎共识意见(2012年,上海)[J].中华消化杂志,2013,33(1):5-15.
[6]中华医学会消化内镜学分会.慢性胃炎的内镜分型分级标准及治疗的试行意见[J].中华消化内镜杂志,2004,21(2):77-78.
[7]中华医学会消化病学分会.慢性胃炎的病理诊断标准[J].中华消化杂志.2007,27(1):49-50.
[8]张万岱,陈治水,危北海.慢性胃炎的中西医结合诊治方案(草案)[J].中国中西医结合杂志,2005,13(2):172-175.
[9]孙佩玉.序贯疗法联合口腔洁治对慢性萎缩性胃炎患者胃幽门螺杆菌根除的近期疗效研究[J].中国全科医学,2015,18(10):1172-1175.
[10]马亚楠,李夏雨,李倩倩,等.血清胃蛋白酶原在胃部疾病中的研究进展[J].中华临床医师杂志:电子版,2013,7(23):10957-10960.
[11]李莉,陈勇毅.中医药防治慢性萎缩性胃炎癌前病变的研究概况[J].浙江中医杂志,2014,49(9):699-701.
[12]陈洁,朱明辉,彭岚,李春仙,崔红,王卫华.血清胃蛋白酶原水平与慢性萎缩性胃炎的相关性分析[J].中国卫生检验杂志,2015,25(21):3649-3650.
[13]章武战,章国东.胃蛋白酶原I.II与胃幽门螺杆菌(Hp)检测的相关性[J].中国卫生检验杂志,2015,25(14):2445-2448.
[14]吴小平.血清胃蛋白酶原Ⅰ/Ⅱ检测对胃癌诊断及预后判断的意义[J].检验医学与临床,2012,9(9):2415-2417.
[15]刘彦晶,金学沫,贾秋颖.三联疗法对幽门螺杆菌相关性慢性浅表性胃炎中医证型的影响[J].中国医药导报,2012,9(23):108-109.
[16]李祎群,谢建群,龚雨萍,孙玉娇.黄芪甲苷对慢性萎缩性胃炎大鼠的影响[J].复旦学报(医学版),2015,42(5):601-606.
[2]中华医学会消化病学分会.中国慢性胃炎共识意见(2012年,上海)[J].现代消化及介入治疗,2013,18(2):119-128.
[3]王晓倩,盛天骄,林一帆,等.健脾清热化瘀法治疗慢性萎缩性胃炎疗效的Meta分析[J].中国中西医结合消化杂志,2015,23(10):678-681.
[4]王胜球,陈柏荣,梁子彬,等.益生菌联合序贯疗法治疗幽门螺杆菌相关性慢性萎缩性胃炎的疗效与安全性分析[J].中国中西医结合消化杂志,2015,23(2):88-90.
[5]中华医学会消化病学分会.中国慢性胃炎共识意见(2012年,上海)[J].中华消化杂志,2013,33(1):5-15.
[6]中华医学会消化内镜学分会.慢性胃炎的内镜分型分级标准及治疗的试行意见[J].中华消化内镜杂志,2004,21(2):77-78.
[7]中华医学会消化病学分会.慢性胃炎的病理诊断标准[J].中华消化杂志.2007,27(1):49-50.
[8]张万岱,陈治水,危北海.慢性胃炎的中西医结合诊治方案(草案)[J].中国中西医结合杂志,2005,13(2):172-175.
[9]孙佩玉.序贯疗法联合口腔洁治对慢性萎缩性胃炎患者胃幽门螺杆菌根除的近期疗效研究[J].中国全科医学,2015,18(10):1172-1175.
[10]马亚楠,李夏雨,李倩倩,等.血清胃蛋白酶原在胃部疾病中的研究进展[J].中华临床医师杂志:电子版,2013,7(23):10957-10960.
[11]李莉,陈勇毅.中医药防治慢性萎缩性胃炎癌前病变的研究概况[J].浙江中医杂志,2014,49(9):699-701.
[12]陈洁,朱明辉,彭岚,李春仙,崔红,王卫华.血清胃蛋白酶原水平与慢性萎缩性胃炎的相关性分析[J].中国卫生检验杂志,2015,25(21):3649-3650.
[13]章武战,章国东.胃蛋白酶原I.II与胃幽门螺杆菌(Hp)检测的相关性[J].中国卫生检验杂志,2015,25(14):2445-2448.
[14]吴小平.血清胃蛋白酶原Ⅰ/Ⅱ检测对胃癌诊断及预后判断的意义[J].检验医学与临床,2012,9(9):2415-2417.
[15]刘彦晶,金学沫,贾秋颖.三联疗法对幽门螺杆菌相关性慢性浅表性胃炎中医证型的影响[J].中国医药导报,2012,9(23):108-109.
[16]李祎群,谢建群,龚雨萍,孙玉娇.黄芪甲苷对慢性萎缩性胃炎大鼠的影响[J].复旦学报(医学版),2015,42(5):601-606.